This NEW series is dedicated to Australian Gastroenterologists.
Hosted by A/Prof Mayur Garg, Director of Gastroenterology, Research Lead for the Division of Medicine at Northern Health, and A/Prof University of Melbourne.
There has been a dramatic increase in the incidence and prevalence of eosinophilic oesophagitis (EoE) in recent years, and not just because of an increased physician awareness of the disease. EoE is a chronic, progressive disease, and long-standing inflammation can lead to oesophageal remodelling, including the formation of oesophageal strictures, negatively impacting patients’ quality of life. In this interview we discuss the diagnosis of EoE and how to effectively manage this condition in both the short- and long-term.
Prof. Rupert Leong, Consultant Gastroenterologist, Concord Hospital, & Prof of Medicine, University of Sydney.
51 minute listen
The past several years have seen an expansion in therapeutic options to care for our patients with inflammatory bowel disease (IBD), with more agents to come in the near future. Conventional therapies such as thiopurines, methotrexate, aminosalicylates, and steroids have been supplemented by the tumour necrosis factor inhibitors, the anti-integrin vedolizumab, the anti-IL-12/23 p40 inhibitor ustekinumab, and more recently the JAK inhibitor tofacitinib. Our expectations and treatment goals have subsequently risen substantially, such that our aim for patients is to achieve sustained clinical remission, achieve endoscopic and possibly histologic and transmural healing, prevent complications, and achieve as close to a normal quality of life as possible for our patients.
Nonetheless, there remains a gap between these goals and what can be achieved in many patients. In this interview we discuss the emerging treatments for moderate to severe IBD.
A/Prof Jake Begun, Director of Gastroenterology, Mater Hospital Brisbane, & A/Prof University of Queensland School of Medicine, & Co-Director Queensland IBD
Multidisciplinary team meetings have proven efficacy in cancer management as well as being widely implemented in the management of chronic diseases like inflammatory bowel disease, however not all treating clinicians (particularly those in rural/regional areas, or even many of those in private practices) have access to these high quality and integrated meetings. Given the potential for an MDT-based approach to potentially improve patient quality of care, patient satisfaction and patient outcomes, it only makes sense that such a service can be offered to the wider gastroenterology community.
In this interview we talk to Jake Begun, who along with his team at Queensland IBD have implemented the first dedicated state-wide virtual MDT in Australia.
Tap the share icon and select 'Add to Home Screen' to add the site to your home screen for quick access!